• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
DNA gyrase, topoisomerase IV, and the 4-quinolones.DNA 回旋酶、拓扑异构酶IV与4-喹诺酮类药物。
Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. doi: 10.1128/mmbr.61.3.377-392.1997.
2
DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.细菌染色体上的DNA促旋酶和拓扑异构酶IV:喹诺酮诱导的DNA切割
J Mol Biol. 1996 May 17;258(4):627-37. doi: 10.1006/jmbi.1996.0274.
3
Topoisomerase IV, not gyrase, decatenates products of site-specific recombination in Escherichia coli.在大肠杆菌中,拓扑异构酶IV而非回旋酶解开位点特异性重组的产物。
Genes Dev. 1997 Oct 1;11(19):2580-92. doi: 10.1101/gad.11.19.2580.
4
Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.细菌拓扑异构酶、抗拓扑异构酶及抗拓扑异构酶耐药性
Clin Infect Dis. 1998 Aug;27 Suppl 1:S54-63. doi: 10.1086/514923.
5
Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.通过引入与金属离子无关的药物-酶相互作用来克服拓扑异构酶 IV 介导的喹诺酮类耐药性。
ACS Chem Biol. 2013 Dec 20;8(12):2660-8. doi: 10.1021/cb400592n. Epub 2013 Sep 30.
6
Topoisomerase IV is a target of quinolones in Escherichia coli.拓扑异构酶IV是喹诺酮类药物在大肠杆菌中的作用靶点。
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11801-5. doi: 10.1073/pnas.92.25.11801.
7
Antibacterial action of quinolones: from target to network.喹诺酮类药物的抗菌作用:从靶点到网络。
Eur J Med Chem. 2013 Aug;66:555-62. doi: 10.1016/j.ejmech.2013.01.057. Epub 2013 Mar 4.
8
Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.吉米沙星和其他氟喹诺酮介导的野生型和耐喹诺酮肺炎链球菌II型拓扑异构酶形成可裂解复合物
Antimicrob Agents Chemother. 2002 Feb;46(2):413-9. doi: 10.1128/AAC.46.2.413-419.2002.
9
The twisted 'life' of DNA in the cell: bacterial topoisomerases.细胞中DNA的“扭曲”生命:细菌拓扑异构酶
Mol Microbiol. 1995 Feb;15(4):601-6. doi: 10.1111/j.1365-2958.1995.tb02369.x.
10
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.金黄色葡萄球菌DNA拓扑异构酶IV的克隆及一级结构:氟喹诺酮类药物的主要作用靶点
Mol Microbiol. 1994 Aug;13(4):641-53. doi: 10.1111/j.1365-2958.1994.tb00458.x.

引用本文的文献

1
Pharmacological evaluation of levofloxacin residue depletion and hemato-biochemical alterations in broiler chickens using a validated HPLC method.使用经过验证的高效液相色谱法对肉鸡中左氧氟沙星残留消除及血液生化改变进行药理学评估。
Sci Rep. 2025 Sep 12;15(1):32496. doi: 10.1038/s41598-025-17575-0.
2
Conservation and divergence of ciprofloxacin persister survival mechanisms between Pseudomonas aeruginosa and Escherichia coli.铜绿假单胞菌和大肠杆菌之间环丙沙星持留菌存活机制的保守性与差异性
PLoS Genet. 2025 Sep 2;21(9):e1011840. doi: 10.1371/journal.pgen.1011840. eCollection 2025 Sep.
3
Synergistic Ciprofloxacin-RWn Peptide Therapy Overcomes Drug Resistance in Gram-Negative Bacteria.环丙沙星与RWn肽协同治疗克服革兰氏阴性菌耐药性。
ACS Omega. 2025 Jun 30;10(32):35698-35705. doi: 10.1021/acsomega.5c02285. eCollection 2025 Aug 19.
4
Metagenomic profiling of pigeon faecal microbiota: insights into microbial diversity, pathogens, and antimicrobial resistance genes.鸽子粪便微生物群的宏基因组分析:对微生物多样性、病原体和抗菌抗性基因的见解
Antonie Van Leeuwenhoek. 2025 Aug 20;118(9):134. doi: 10.1007/s10482-025-02148-y.
5
Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design.喹啉探索:通过合理药物设计开发下一代治疗药物的犬尿喹啉酸策略
Pharmaceuticals (Basel). 2025 Apr 22;18(5):607. doi: 10.3390/ph18050607.
6
New Insights into the Geometry and Topology of DNA Replication Intermediates.DNA复制中间体的几何结构和拓扑结构新见解。
Biology (Basel). 2025 Apr 26;14(5):478. doi: 10.3390/biology14050478.
7
An interbacterial cysteine protease toxin inhibits cell growth by targeting type II DNA topoisomerases GyrB and ParE.一种细菌间的半胱氨酸蛋白酶毒素通过靶向II型DNA拓扑异构酶GyrB和ParE来抑制细胞生长。
PLoS Biol. 2025 May 27;23(5):e3003208. doi: 10.1371/journal.pbio.3003208. eCollection 2025 May.
8
What Do We Know About and Oxidative Stress? Resistance, Virulence, New Targets, and Therapeutic Alternatives.关于[具体内容缺失]和氧化应激我们了解什么?抗性、毒力、新靶点及治疗选择。
Toxics. 2025 May 13;13(5):390. doi: 10.3390/toxics13050390.
9
Antibiotic Resistance Gene Expression in Veterinary Probiotics: Two Sides of the Coin.兽用益生菌中的抗生素抗性基因表达:硬币的两面
Vet Sci. 2025 Mar 2;12(3):217. doi: 10.3390/vetsci12030217.
10
Investigating the Impact of Antibiotics on Environmental Microbiota Through Machine Learning Models.通过机器学习模型研究抗生素对环境微生物群的影响。
IET Syst Biol. 2025 Jan-Dec;19(1):e70009. doi: 10.1049/syb2.70009.

本文引用的文献

1
Nalidixic Acid and the Metabolism of Escherichia coli.萘啶酸与大肠杆菌的代谢
J Bacteriol. 1970 Dec;104(3):1168-75. doi: 10.1128/jb.104.3.1168-1175.1970.
2
MECHANISM OF ACTION OF NALIDIXIC ACID ON ESCHERICHIA COLI.II. INHIBITION OF DEOXYRIBONUCLEIC ACID SYNTHESIS.萘啶酸对大肠杆菌的作用机制。二、脱氧核糖核酸合成的抑制
J Bacteriol. 1965 Apr;89(4):1068-74. doi: 10.1128/jb.89.4.1068-1074.1965.
3
Exploiting nucleotide thiophosphates to probe mechanistic aspects of Escherichia coli DNA gyrase.利用硫代磷酸核苷酸探究大肠杆菌DNA促旋酶的作用机制。
Biochemistry. 1997 May 20;36(20):6059-68. doi: 10.1021/bi962725e.
4
Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.金黄色葡萄球菌和大肠杆菌II型DNA拓扑异构酶的差异行为
Antimicrob Agents Chemother. 1996 Dec;40(12):2714-20. doi: 10.1128/AAC.40.12.2714.
5
Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.司帕沙星对肺炎链球菌中DNA回旋酶的靶向作用:喹诺酮类药物对回旋酶或拓扑异构酶IV的选择性靶向作用
Antimicrob Agents Chemother. 1997 Feb;41(2):471-4. doi: 10.1128/AAC.41.2.471.
6
Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV.大肠杆菌喹诺酮耐药位点nfxD是编码拓扑异构酶IV一个亚基的parE基因的突变等位基因。
Antimicrob Agents Chemother. 1997 Jan;41(1):175-9. doi: 10.1128/AAC.41.1.175.
7
Conversion of DNA gyrase into a conventional type II topoisomerase.DNA促旋酶向传统II型拓扑异构酶的转变。
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14416-21. doi: 10.1073/pnas.93.25.14416.
8
Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis.
J Infect Dis. 1996 Nov;174(5):1127-30. doi: 10.1093/infdis/174.5.1127.
9
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.拓扑异构酶IV和DNA促旋酶作为环丙沙星在肺炎链球菌中的作用靶点。
Antimicrob Agents Chemother. 1996 Oct;40(10):2321-6. doi: 10.1128/AAC.40.10.2321.
10
ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.肺炎链球菌DNA拓扑异构酶IV的ParC亚基是氟喹诺酮类药物的主要作用靶点,并与DNA回旋酶A亚基协同形成耐药表型。
Antimicrob Agents Chemother. 1996 Oct;40(10):2252-7. doi: 10.1128/AAC.40.10.2252.

DNA 回旋酶、拓扑异构酶IV与4-喹诺酮类药物。

DNA gyrase, topoisomerase IV, and the 4-quinolones.

作者信息

Drlica K, Zhao X

机构信息

Public Health Research Institute, New York, New York 10016, USA.

出版信息

Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. doi: 10.1128/mmbr.61.3.377-392.1997.

DOI:10.1128/mmbr.61.3.377-392.1997
PMID:9293187
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC232616/
Abstract

For many years, DNA gyrase was thought to be responsible both for unlinking replicated daughter chromosomes and for controlling negative superhelical tension in bacterial DNA. However, in 1990 a homolog of gyrase, topoisomerase IV, that had a potent decatenating activity was discovered. It is now clear that topoisomerase IV, rather than gyrase, is responsible for decatenation of interlinked chromosomes. Moreover, topoisomerase IV is a target of the 4-quinolones, antibacterial agents that had previously been thought to target only gyrase. The key event in quinolone action is reversible trapping of gyrase-DNA and topoisomerase IV-DNA complexes. Complex formation with gyrase is followed by a rapid, reversible inhibition of DNA synthesis, cessation of growth, and induction of the SOS response. At higher drug concentrations, cell death occurs as double-strand DNA breaks are released from trapped gyrase and/or topoisomerase IV complexes. Repair of quinolone-induced DNA damage occurs largely via recombination pathways. In many gram-negative bacteria, resistance to moderate levels of quinolone arises from mutation of the gyrase A protein and resistance to high levels of quinolone arises from mutation of a second gyrase and/or topoisomerase IV site. For some gram-positive bacteria, the situation is reversed: primary resistance occurs through changes in topoisomerase IV while gyrase changes give additional resistance. Gyrase is also trapped on DNA by lethal gene products of certain large, low-copy-number plasmids. Thus, quinolone-topoisomerase biology is providing a model for understanding aspects of host-parasite interactions and providing ways to investigate manipulation of the bacterial chromosome by topoisomerases.

摘要

多年来,DNA促旋酶一直被认为既负责解开复制后的子代染色体,又负责控制细菌DNA中的负超螺旋张力。然而,1990年发现了一种促旋酶的同源物——拓扑异构酶IV,它具有强大的解连环活性。现在已经清楚,负责解开相互连接的染色体的是拓扑异构酶IV,而不是促旋酶。此外,拓扑异构酶IV是4-喹诺酮类抗菌剂的作用靶点,这类抗菌剂以前被认为只作用于促旋酶。喹诺酮作用的关键事件是促旋酶-DNA和拓扑异构酶IV-DNA复合物的可逆捕获。与促旋酶形成复合物后,会迅速、可逆地抑制DNA合成、停止生长并诱导SOS反应。在较高的药物浓度下,随着双链DNA断裂从捕获的促旋酶和/或拓扑异构酶IV复合物中释放出来,细胞会死亡。喹诺酮诱导的DNA损伤的修复主要通过重组途径进行。在许多革兰氏阴性细菌中,对中等水平喹诺酮的耐药性源于促旋酶A蛋白的突变,而对高水平喹诺酮的耐药性源于第二个促旋酶和/或拓扑异构酶IV位点的突变。对于一些革兰氏阳性细菌,情况则相反:主要耐药性通过拓扑异构酶IV的变化产生,而促旋酶的变化则提供额外的耐药性。促旋酶也会被某些大型低拷贝数质粒的致死基因产物捕获在DNA上。因此,喹诺酮-拓扑异构酶生物学为理解宿主-寄生虫相互作用的各个方面提供了一个模型,并为研究拓扑异构酶对细菌染色体的操纵提供了方法。